A genome-wide screen for variants influencing certolizumab pegol response in a moderate to severe rheumatoid arthritis population.
Certolizumab pegol (CZP) is a PEGylated Fc-free tumor necrosis factor (TNF) inhibitor antibody approved for use in the treatment of rheumatoid arthritis (RA), Crohn's disease, psoriatic arthritis, axial spondyloarthritis and psoriasis. In a clinical trial of patients with severe RA, CZP improve...
| Hoofdauteurs: | , , , , , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
Public Library of Science (PLoS)
2022-01-01
|
| Reeks: | PLoS ONE |
| Online toegang: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0261165&type=printable |